Intellia Therapeutics (NTLA) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for Intellia Therapeutics (NTLA) over the last 6 years, with Q3 2025 value amounting to -$0.92.
- Intellia Therapeutics' EPS (Weighted Average and Diluted) rose 3134.33% to -$0.92 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.26, marking a year-over-year increase of 2169.12%. This contributed to the annual value of -$4.92 for FY2024, which is 614.53% up from last year.
- Intellia Therapeutics' EPS (Weighted Average and Diluted) amounted to -$0.92 in Q3 2025, which was up 3134.33% from -$0.98 recorded in Q2 2025.
- Intellia Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.92 during Q3 2025, with a 5-year trough of -$1.96 in Q1 2022.
- Over the past 5 years, Intellia Therapeutics' median EPS (Weighted Average and Diluted) value was -$1.3 (recorded in 2022), while the average stood at -$1.27.
- Per our database at Business Quant, Intellia Therapeutics' EPS (Weighted Average and Diluted) plummeted by 5328.84% in 2022 and then soared by 4030.61% in 2023.
- Intellia Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$1.13 in 2021, then dropped by 22.43% to -$1.38 in 2022, then fell by 4.02% to -$1.44 in 2023, then rose by 11.34% to -$1.27 in 2024, then increased by 27.72% to -$0.92 in 2025.
- Its last three reported values are -$0.92 in Q3 2025, -$0.98 for Q2 2025, and -$1.1 during Q1 2025.